VELOCITY-Lung: A phase (Ph) 2 study evaluating safety and efficacy of domvanalimab (dom) + zimberelimab (zim) + sacituzumab govitecan (SG), or etrumadenant (etruma) + dom + zim, or etruma + zim in patients (pts) with treatment-naïve metastatic non-small cell lung cancer (mNSCLC).

Authors

Alexander I. Spira

Virginia Cancer Specialists, Fairfax, VA

Alexander I. Spira , Joanne Chiu , Chin Chou Wang , Alona Zer , John Conibear , Patrick Hoang Phuong , Joseph K. Park , Anna Seto , Jie Zhang , Byoung Chul Cho

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.

First Author: Christos Chouaid

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

STAR-121: A phase 3, randomized study of domvanalimab (DOM) and zimberelimab (ZIM) in combination with chemotherapy vs pembrolizumab (pembro) and chemotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC) with no actionable gene alterations.

First Author: Delvys Rodriguez-Abreu

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.

First Author: Benjamin Besse

insert_chart_outlined

Poster

2023 ASCO Quality Care Symposium

bookmark_border

Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).

First Author: Ruchit Shah